


FMF-03-145-1



Chemical Formula: C₃₀H₂₉N₇O₃

Molecular Weight: 535.61

| Category | Parameter | Description |
|---------------------------|------------------------------------|---|
| Compound | Name | FMF-03-145-1 |
| | Citation | Bioorg Med Chem Lett. 2017 Sep 15;27(18):4405-4408. https://doi.org/10.1016/j.bmcl.2017.08.016 |
| | Chemical descriptors | CC1=CC2=C(N(C)C(N=C(NC3=CC=C(NC(C4=CC=C(NC(CC)=O)C=C4)=O)C=C3)N=C5)=C5N(C)C2=O)C=C1 |
| | Chemical name | 4-propionamido- <i>N</i> -(4-((5,8,11-trimethyl-6-oxo-6,11-dihydro-5 <i>H</i> -benzo[<i>e</i>]pyrimido[5,4- <i>b</i>][1,4]diazepin-2-yl)amino)phenyl)benzamide |
| | Entries in chemical databases | |
| | Availability | |
| | Papers that use the compounds | |
| <i>In vitro</i> profiling | Target (potency) | Aurora A (IC ₅₀ = 52 nM +/- 3.0 nM) |
| | Target (potency) | Aurora B (IC ₅₀ = 41 nM +/- 4.5 nM) |
| | Target (potency) | Aurora C (IC ₅₀ = 53 nM +/- 2.4 nM) |
| | Selectivity | Exclusively on-target activity detected by KINOMEscan® at 1 μM compound concentration. PLK4 biochemical IC ₅₀ = 82 nM |
| | Potential reactivity | Cysteine reactive |
| | SAR | Described in paper |
| | Mechanism of inhibition | Reversible |
| | Structure of target-probe complex | 5ONE |
| Cellular profiling | Validation of cellular target | Does dependent inhibition of pAurora A (Aurora A substrate) and pH3 S10 (Aurora B substrate) in HCT116 cells. Effects on cell cycle consistent with selective on-target inhibition. |
| | Validation of cellular specificity | |
| Pharmacodynamics | | |
| Pharmacokinetics | | |

Synthetic scheme

See FMF-01-086-2
